Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy

Efrat Luttwak; Mitchell R Smith; Andrew D Zelenetz

doi:10.1080/14656566.2023.2223963

Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy

Expert Opin Pharmacother. 2023 May-Aug;24(12):1331-1334. doi: 10.1080/14656566.2023.2223963. Epub 2023 Jun 12.

Authors

Efrat Luttwak¹, Mitchell R Smith², Andrew D Zelenetz¹

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
² The Follicular Lymphoma Foundation, Washington, USA.

PMID: 37294016
DOI: 10.1080/14656566.2023.2223963

No abstract available

Keywords: Clinical trial endpoints; FDA approval; Non-Hodgkin lymphoma; PI3K inhibitors; drug development; indolent B cell lymphoma; relapsed/refractory.

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Humans
Lymphoma, B-Cell* / drug therapy
Lymphoma, Non-Hodgkin* / drug therapy
Phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors / therapeutic use

Substances

Phosphoinositide-3 Kinase Inhibitors
Phosphatidylinositol 3-Kinases
Antineoplastic Agents